Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00255918 · ClinicalTrials.gov registry record · Phase 1
Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients
A Phase 1 study, sponsored by University of Colorado, Denver.
- Completed
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT00255918 is a Phase 1 study that has completed, run by University of Colorado, Denver. The registered enrollment target is 12 participants.
The verdict
NCT00255918, a Phase 1 study, has completed, sponsored by University of Colorado, Denver.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This study will determine the effectiveness of a drug, dimethoxbenzylidene anabaseine, in producing beneficial effects similar to that of nicotine in individuals with schizophrenia.
Interventions
- DRUG Placebo
- DRUG Dimethoxybenzylidene anabaseine (DMXB-A)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00255918
The ClinicalTrials.gov registry entry for NCT00255918 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Colorado, Denver, which has 1,283 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00255918 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00255918 about?
NCT00255918 is a clinical study titled "Investigation of the Drug Dimethoxbenzylidene Anabaseine in Treating Schizophrenia Patients". This study will determine the effectiveness of a drug, dimethoxbenzylidene anabaseine, in producing beneficial effects similar to that of nicotine in individuals with schizophrenia.
What is the current status of trial NCT00255918?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2004-03. Estimated completion is 2005-10.
What interventions are being tested in trial NCT00255918?
The interventions under investigation include: Placebo (DRUG), Dimethoxybenzylidene anabaseine (DMXB-A) (DRUG).
Who is sponsoring clinical trial NCT00255918?
This trial is sponsored by University of Colorado, Denver, which has 1,283 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.